Comparative Pharmacology
Head-to-head clinical analysis: AZSTARYS versus FOCALIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZSTARYS versus FOCALIN XR.
AZSTARYS vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Renal (approximately 90% as unchanged drug and metabolites)
Category C
Category C
CNS Stimulant
CNS Stimulant